Pharma-test DFC1220SP Semi-Automatic Dissolution Testing System

Overview

The Pharma-test DFC1220SP Semi-Automatic Dissolution Testing System is an engineered platform for controlled, reproducible evaluation of drug release profiles from solid oral dosage forms—including immediate-release tablets, extended-release capsules, and multiparticulate systems—under pharmacopoeial conditions. Based on the paddle (USP Apparatus 2) and basket (USP Apparatus 1) dissolution methodologies, the DFC1220SP integrates a precision-controlled dissolution bath (PTWS 1220) with modular automation components to support offline sampling workflows compliant with regulatory requirements for method validation and quality control. Unlike fully automated online systems, the DFC1220SP maintains operational transparency and procedural flexibility while enabling high-integrity sample collection at defined timepoints—critical for stability-indicating assays, comparative dissolution studies, and bioequivalence support.

Key Features

• Eight-position dissolution bath (PTWS 1220) with independent vessel alignment, PTFE-coated shafts, and full immersion geometry ensuring consistent hydrodynamic conditions across all vessels.
• Modular sampling architecture: supports either in-situ fixed-probe sampling (continuous medium immersion) or retractable EPE-1220 probe-based sampling with programmable timing and sequential vessel access.
• Dual PT-SP8 precision syringe pumps (2 × 10 mL capacity) for accurate, pulse-free media withdrawal and replacement—enabling automated medium replenishment to maintain sink conditions during prolonged dissolution runs.
• PTFC-16 fraction collector with refrigerated sample storage (4 °C), programmable vial positioning, and barcode-compatible tube labeling for traceable sample handling.
• Optional real-time temperature monitoring via ITM-1220 inline thermistor probes placed directly within each dissolution vessel, delivering ±0.2 °C accuracy referenced to calibrated RTD sensors.
• Optional tablet drop alignment modules (TM-1220 or TMA-1220) ensure repeatable tablet placement at the vessel centerline—minimizing positional variability that can affect dissolution kinetics, particularly for floating or buoyant dosage forms.
• Comprehensive peripheral compatibility: accepts Ismatec IPC/Reglo RF peristaltic pumps or CAT PicoPlus piston pumps as alternatives to syringe-driven media handling, accommodating diverse lab preferences and maintenance protocols.

Sample Compatibility & Compliance

The DFC1220SP is validated for use with USP Apparatus 1 (basket) and Apparatus 2 (paddle), supporting standard 1000 mL vessels and compatible with non-standard geometries (e.g., mini-vessels, flow-through cells) via adapter kits. It meets mechanical calibration requirements outlined in USP and , as well as European Pharmacopoeia monographs 2.9.3 (Dissolution Test for Solid Dosage Forms) and 2.9.4 (Dissolution Test for Transdermal Systems). All critical parameters—including vessel temperature uniformity, paddle/basket wobble, centering tolerance, and rotational speed stability—are verifiable using Pharma-test’s certified calibration tools (e.g., PT-CAL-1220 kit). The system architecture supports audit-ready documentation under GLP and GMP environments, with optional integration into electronic lab notebooks (ELNs) via RS-232 or USB virtual COM port interfaces.

Software & Data Management

Operation is managed through Pharma-test’s proprietary PT-Control software (Windows-based), which provides intuitive scheduling of dissolution timelines, sampling sequences, pump actuation, and temperature logging. While the DFC1220SP does not include integrated UV/Vis detection, its output files (CSV-formatted time-stamped sampling logs, pump status reports, and temperature traces) are structured for direct import into LIMS, CDS, or statistical analysis platforms (e.g., JMP, Simca, or Python/Pandas workflows). Optional PT-RP80 thermal printer enables hard-copy generation of test reports—including run ID, operator, date/time stamps, vessel assignments, and deviation flags—supporting 21 CFR Part 11-compliant record retention when paired with user-access controls and electronic signature modules.

Applications

• Comparative dissolution profiling of generic vs. reference listed drugs (RLDs) per FDA guidance.
• Formulation development screening for excipient impact on release kinetics.
• Stability-indicating dissolution testing across accelerated and long-term storage conditions.
• Quality control release testing for commercial batches under approved dissolution specifications.
• Investigation of dose-dumping risk in modified-release products using pH-shift or surfactant challenge protocols.
• Support for biowaiver submissions where dissolution similarity is a key regulatory criterion (e.g., WHO, ICH Q5A).

FAQ

Is the DFC1220SP compliant with 21 CFR Part 11?
Yes—when configured with PT-Control software v3.2+, user authentication, audit trail logging, and electronic signature modules, the system supports Part 11 compliance for electronic records and signatures in regulated environments.
Can the system be upgraded to full automation?
The DFC1220SP serves as the foundation for Pharma-test’s fully automated DFC-1220 series; upgrade paths include integration with UV/Vis spectrophotometers (e.g., PT-UV1220), autosamplers with filtration, and closed-loop feedback control modules.
What maintenance is required for the PT-SP8 syringe pumps?
Routine maintenance includes quarterly calibration verification using gravimetric methods, annual replacement of syringe seals, and periodic cleaning of fluid paths with ethanol/water rinses to prevent crystallization of dissolved APIs.
Does the system support non-USP dissolution apparatus types?
Yes—via optional hardware adapters, the PTWS 1220 bath accommodates Apparatus 3 (reciprocating cylinder), Apparatus 4 (flow-through cell), and custom fixtures for transdermal or implantable dosage forms.
How is vessel temperature uniformity verified?
Pharma-test provides a certified calibration protocol (PT-CAL-1220) using six calibrated NIST-traceable PT100 probes placed at standardized radial and axial positions within the bath, with acceptance criteria aligned to USP Annex A (±0.2 °C max deviation).